




The relative strengths and weaknesses of Sagent Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sagent Pharmaceuticals Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Sagent Pharmaceuticals Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 323%, being 60% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	191,592
Cost of Goods Sold	0
Intangible Assets	78,350
Liabilities, Current	83,655
Liabilities, Non-Current	2,963
Other Assets	60,029
Other Compr. Net Income	-14,108
Other Expenses	258,312
Other Liabilities	12,021
Other Net Income	-2,790
Other Revenues	318,296
Property and Equipment	19,761
Research and Development	29,145
Selling, General and Administrative Expense	49,931

Output Variable	Value in 1000 USD
Assets	349,732
Liabilities	98,639
Expenses	337,388
Revenues	318,296
Stockholders Equity	251,093
Net Income	-21,882
Comprehensive Net Income	-28,936
BaseVar	560,476
ECR before Limited Liability	231%
Economic Capital Ratio	323%